Jeffrey Crook, MD
Cardiovascular Disease · Norman, OKNPI 1730180324
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,345 of the $6,213 with a category attached, or 86.0%. 28 manufacturers reported payments, led by Medtronic at 34.6% of the total. Reporting peaked in 2019 at $1,801 and has fallen 74.2% since, to $465 in 2025.
Across 269 payments — averaging $23.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Johnson & Johnson$597
- Novartis$415
- Kowa Pharmaceuticals America, Inc.$366
- AstraZeneca$328
- Actelion Pharmaceuticals US, Inc.$307
- plus $2K from 22 others
What the payments were for
- Travel & lodging$85914%
- Food & beverage$5,34586%
- Education$100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 17 | $2,153 |
| Johnson & Johnson | 48 | $597 |
| Novartis | 24 | $415 |
| Kowa Pharmaceuticals America, Inc. | 50 | $366 |
| AstraZeneca | 23 | $328 |
| Actelion Pharmaceuticals US, Inc. | 13 | $307 |
| Abbott | 10 | $274 |
| Boston Scientific | 3 | $253 |
| Amgen | 10 | $194 |
| Philips North America LLC | 8 | $170 |
| Novo Nordisk | 7 | $136 |
| Pfizer | 8 | $135 |
| Amarin Pharma, Inc. | 8 | $133 |
| E.r. Squibb & Sons, L.L.C. | 7 | $107 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $104 |
| Cvrx, Inc. | 1 | $104 |
| Sanofi-aventis U.S. LLC | 5 | $97 |
| Esperion Therapeutics, Inc. | 5 | $65 |
| Kestra Medical Technology Services, Inc. | 2 | $64 |
| Merck | 3 | $41 |
| Abiomed | 1 | $32 |
| Inari Medical, Inc. | 1 | $27 |
| Irhythm Technologies, Inc. | 2 | $25 |
| Vifor Pharma, Inc. | 1 | $19 |
| Chiesi USA, Inc. | 1 | $18 |
| Bayer | 1 | $18 |
| Baxter Healthcare | 1 | $17 |
| Boehringer Ingelheim | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Azure$1,052
- Micra$262
- AURORA EV-ICD MRI SURESCAN$251
- Watchman$238
- Amplia MRI$165
- MitraClip$145
- ONYX FRONTIER$123
- Telescope$121
- Barostim Neo System$104
How this compares
$6,213 in reported general payments places this provider in the 70th percentile of 164 cardiovascular disease providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 281 | $359,553 |
| XareltoRivaroxaban | 113 | $126,795 |
| EntrestoSacubitril/Valsartan | 53 | $65,395 |
| FarxigaDapagliflozin Propanediol | 67 | $62,188 |
| Praluent PenAlirocumab | 17 | $12,867 |
| BrilintaTicagrelor | 16 | $11,023 |
| JardianceEmpagliflozin | 12 | $9,618 |
| Prasugrel Hcl | 73 | $8,936 |
| LivaloPitavastatin Calcium | 20 | $7,289 |
| Repatha SureclickEvolocumab | 13 | $7,003 |
| Nebivolol Hcl | 64 | $5,621 |
| Metoprolol Succinate | 314 | $4,900 |
| Carvedilol ErCarvedilol Phosphate | 13 | $4,889 |
| Atorvastatin Calcium | 303 | $4,602 |
| Irbesartan | 142 | $4,351 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $135 | $359,553281 claims |
| Johnson & JohnsonXarelto | $597 | $126,795113 claims |
| AstraZenecaFarxiga, Brilinta | $328 | $73,21183 claims |
| NovartisEntresto | $415 | $65,39553 claims |
| Boehringer IngelheimJardiance | $16 | $9,61812 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $366 | $7,28920 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 164 cardiovascular disease providers in Oklahoma.
Other cardiovascular disease in Norman
- Archana GautamNorman$21K
- Muhammad SalimNorman$8K
- Michael SellersNorman$6K
- Norman AyersNorman$6K
- Frank GaffneyTulsa$211K
- Anderson MehrleBartlesville$129K
- Aly El BanayosyOklahoma City$54K
- Dwight ReynoldsOklahoma City$47K
- Mohamad KhattabTulsa$47K
- Udho ThadaniOklahoma City$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.